ArticleCell reports2021
Loss of FBXO31-mediated degradation of DUSP6 dysregulates ERK and PI3K-AKT signaling and promotes prostate tumorigenesis.
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 35 citations in OpenAlex.
- Dual-specificity phosphatase 6 interferes with the repressive activity of forkhead box O1 towards CYP4A11 that mediates lipid accumulation in the liver.Scientific reports · 2026Article
- FBXO31-induced ABL2 ubiquitination increases cystine-glutamate antiporter-mediated ferroptosis and inhibits malignant progression in triple-negative breast cancer.American journal of translational research · 2026Article
- Research advancements regarding the relationship between FBXO2 and malignant tumors (Review).Molecular medicine reports · 2025Review
- F-box proteins in cancer: from cancer cells to the tumor microenvironment.Cell communication and signaling : CCS · 2025Review
- DUSP6 is upregulated in metastasis and influences migration and metabolism in pancreatic cancer cells.Scientific reports · 2025Article
- Endometrial Mesenchymal Stem Cell-Derived Exosomal miR-4669 Promotes EMT in Adenomyosis by Inducing M2 Macrophage Polarization via the DUSP6/ERK Pathway.Reproductive sciences (Thousand Oaks, Calif.) · 2025Article
- Molecular mechanisms of CAND2 in regulating SCF ubiquitin ligases.Nature communications · 2025Article
- FBXO31-mediated ubiquitination of OGT maintains O-GlcNAcylation homeostasis to restrain endometrial malignancy.Nature communications · 2025Article
- MiR-3571 modulates traumatic brain injury by regulating the PI3K/AKT signaling pathway via Fbxo31.Cell biochemistry and biophysics · 2024Article
- Iron homeostasis and ferroptosis in human diseases: mechanisms and therapeutic prospects.Signal transduction and targeted therapy · 2024Review
- Ubiquitination Insight from Spinal Muscular Atrophy-From Pathogenesis to Therapy: A Muscle Perspective.International journal of molecular sciences · 2024Review
- Sevoflurane augments neuroinflammation by regulating DUSP6 via YTHDF1 in postoperative cognitive dysfunction.Toxicology research · 2024Article
- Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer.Nature communications · 2024Article
- KLF9‑regulated FBXO31 inhibits the progression of endometrial cancer and enhances the sensitivity of endometrial cancer cells to cisplatin.Experimental and therapeutic medicine · 2024Article
- FBXO31 is upregulated by METTL3 to promote pancreatic cancer progression via regulating SIRT2 ubiquitination and degradation.Cell death & disease · 2024Article
- Article
- Compartmentalization of androgen receptors at endogenous genes in living cells.Nucleic acids research · 2023Article
- Targeting PI3K/Akt signaling in prostate cancer therapy.Journal of cell communication and signaling · 2023Review
- A DUSP6 inhibitor suppresses inflammatory cardiac remodeling and improves heart function after myocardial infarction.Disease models & mechanisms · 2023Article
- NRP1 promotes prostate cancer progression via modulating EGFR-dependent AKT pathway activation.Cell death & disease · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Shanshan DuanDepartment of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, The Alexandria Center for Life Science, New York, NY 10016, USA; Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, The Alexandria Center for Life Science, New York, NY 10016, USA.
Loredana MoroDepartment of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, The Alexandria Center for Life Science, New York, NY 10016, USA; Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, The Alexandria Center for Life Science, New York, NY 10016, USA.
Rui QuDepartment of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, The Alexandria Center for Life Science, New York, NY 10016, USA; Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, The Alexandria Center for Life Science, New York, NY 10016, USA.
Daniele SimoneschiDepartment of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, The Alexandria Center for Life Science, New York, NY 10016, USA; Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, The Alexandria Center for Life Science, New York, NY 10016, USA.
Hyunwoo ChoDepartment of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, The Alexandria Center for Life Science, New York, NY 10016, USA; Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, The Alexandria Center for Life Science, New York, NY 10016, USA.
Shaowen JiangDepartment of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, The Alexandria Center for Life Science, New York, NY 10016, USA; Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, The Alexandria Center for Life Science, New York, NY 10016, USA.
Huiyong ZhaoProgram in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
Qing ChangProgram in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
Elisa de StanchinaProgram in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
Arnaldo A ArbiniLaura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, The Alexandria Center for Life Science, New York, NY 10016, USA; Department of Pathology, NYU Grossman School of Medicine, The Alexandria Center for Life Science, New York, NY 10016, USA.
Michele PaganoDepartment of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, The Alexandria Center for Life Science, New York, NY 10016, USA; Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, The Alexandria Center for Life Science, New York, NY 10016, USA; Howard Hughes Medical Institute, NYU Grossman School of Medicine, The Alexandria Center for Life Science, New York, NY 10016, USA. Electronic address: michele.pagano@nyumc.org.
New York University · USMemorial Sloan Kettering Cancer Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTRAINING PROGRAM IN MOLECULAR ONCOLOGY &IMMUNOLOGYT32CA009161 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CARROLL, WILLIAM L., LEVY, DAVID E · 1985 to 2020
$13.3MF-Box Proteins: Deregulated Cell Cycle Control and Proteolysis in CancerR01CA076584 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI PAGANO, MICHELE · 1998 to 2021
$4.5MRegulation of the cell proliferation by CRL ubiquitin ligases-diversity supplementR35GM136250 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MICHELE PAGANO · 2020 to 2026
$2.7MNCI NIH HHS P30 CA008748NCI NIH HHS R01 CA076584NCI NIH HHS T32 CA009161NIGMS NIH HHS R35 GM136250
Abstract
FBXO31 is the substrate receptor of one of many CUL1-RING ubiquitin ligase (CRL1) complexes. Here, we show that low FBXO31 mRNA levels are associated with high pre-operative prostate-specific antigen (PSA) levels and Gleason grade in human prostate cancer. Mechanistically, the ubiquitin ligase CRL1
Indexed as
AnimalsAntineoplastic AgentsCell Line, TumorCullin ProteinsCyclohexylaminesDual Specificity Phosphatase 6Enzyme ActivationEnzyme InhibitorsEnzyme StabilityExtracellular Signal-Regulated MAP KinasesF-Box ProteinsGene Expression Regulation, NeoplasticHEK293 CellsHumansIndenesMale2-benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-oneAntineoplastic AgentsCullin ProteinsCyclohexylaminesDual Specificity Phosphatase 6DUSP6 protein, humanEnzyme InhibitorsExtracellular Signal-Regulated MAP KinasesF-Box ProteinsFBXO31 protein, humanIndenesPhosphatidylinositol 3-KinaseProto-Oncogene Proteins c-aktTumor Suppressor ProteinsAKTBCICRLDUSP6ERKF-box proteinFBXO31prostate cancerubiquitinubiquitin ligases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.